Penumbra Inc (PEN)
Pretax margin
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | 79,674 | 48,644 | 38,375 | 17,628 | 3,872 | -44,210 | -38,644 | -26,322 | -7,841 | 33,618 | 6,347 | -20,877 | -34,463 | -22,831 | 9,285 | 39,227 | 51,589 | 46,996 | 16,218 | 10,798 |
Revenue (ttm) | US$ in thousands | 1,058,522 | 995,059 | 937,791 | 884,636 | 847,133 | 829,928 | 806,367 | 782,281 | 747,590 | 710,477 | 671,436 | 592,287 | 560,412 | 538,777 | 527,203 | 556,295 | 547,405 | 522,935 | 495,239 | 470,676 |
Pretax margin | 7.53% | 4.89% | 4.09% | 1.99% | 0.46% | -5.33% | -4.79% | -3.36% | -1.05% | 4.73% | 0.95% | -3.52% | -6.15% | -4.24% | 1.76% | 7.05% | 9.42% | 8.99% | 3.27% | 2.29% |
December 31, 2023 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $79,674K ÷ $1,058,522K
= 7.53%
The pretax margin of Penumbra Inc has shown a consistent improvement over the quarters, indicating better efficiency in managing operating expenses relative to revenue. The company's pretax margin has gradually increased from negative figures in the first and second quarters of 2022 to a positive 7.52% in the fourth quarter of 2023. This trend suggests that Penumbra Inc has been successful in controlling costs and increasing profitability before taxes. It is important for Penumbra Inc to sustain this positive momentum to ensure long-term financial health and stability.
Peer comparison
Dec 31, 2023
Company name
Symbol
Pretax margin
Penumbra Inc
PEN
7.53%
3M Company
MMM
-29.64%
Artivion Inc
AORT
-6.52%
Baxter International Inc
BAX
17.65%
Becton Dickinson and Company
BDX
7.66%
Boston Scientific Corp
BSX
14.20%
DexCom Inc
DXCM
19.72%
Embecta Corp
EMBC
5.72%
Glaukos Corp
GKOS
-44.11%
Globus Medical
GMED
10.54%
Haemonetics Corporation
HAE
5.85%